Daniela Pietra

List of Publications by Year
in descending order

115 papers	10,382 citations	47006 47 h-index	32842 100 g-index
117 all docs	117 docs citations	117 times ranked	7187 citing authors

#	Article	IF	Citations
1	Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. New England Journal of Medicine, 2013, 369, 2379-2390.	27.0	1,698
2	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	7.2	653
3	JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood, 2014, 123, 1544-1551.	1.4	507
4	Clinical significance of somatic mutation in unexplained blood cytopenia. Blood, 2017, 129, 3371-3378.	1.4	379
5	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood, 2015, 126, 233-241.	1.4	361
6	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	1.4	340
7	A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia, 2010, 24, 1574-1579.	7.2	321
8	Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood, 2008, 111, 1686-1689.	1.4	264
9	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	7.2	263
10	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017, 31, 2726-2731.	7.2	242
11	Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica, 2008, 93, 1645-1651.	3.5	241
12	Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood, 2006, 107, 3676-3682.	1.4	236
13	Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood, 2016, 127, 325-332.	1.4	228
14	Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes. Journal of Clinical Oncology, 2009, 27, 754-762.	1.6	225
15	Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood, 2014, 124, 1513-1521.	1.4	222
16	Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia, 2016, 30, 431-438.	7.2	216
17	Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood, 2011, 117, 2813-2816.	1.4	190
18	Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood, 2005, 106, 3374-3376.	1.4	166

#	Article	IF	Citations
19	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood, 2011, 118, 167-176.	1.4	153
20	Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood, 2007, 110, 485-489.	1.4	148
21	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	1.4	137
22	Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood, 2009, 114, 3538-3545.	1.4	135
23	Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia, 2010, 24, 1290-1298.	7.2	135
24	Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation. Journal of Clinical Oncology, 2007, 25, 5630-5635.	1.6	130
25	Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia, 2015, 29, 66-75.	7.2	122
26	Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia, 2006, 20, 549-555.	7.2	118
27	A dynamic prognostic model to predict survival in postâ€“polycythemia vera myelofibrosis. Blood, 2008, 111, 3383-3387.	1.4	108
28	Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. American Journal of Hematology, 2012, 87, 245-250.	4.1	107
29	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	1.4	105
30	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood, 2013, 121, 4388-4395.	1.4	83
31	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer, 2006, 107, 2206-2211.	4.1	82
32	Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica, 2009, 94, 38-45.	3.5	82
33	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	4.1	80
34	The â€˜GGCCâ€™ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia, 2009, 23, 1924-1926.	7.2	68
35	The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica, 2011, 96, 367-374.	3.5	67
36	Clinical significance of genetic aberrations in secondary acute myeloid leukemia. American Journal of Hematology, 2012, 87, 1010-1016.	4.1	67

#	Article	IF	Citations
37	CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood, 2014, 123, 2416-2419.	1.4	66
38	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica, 2011, 96, 454-458.	3.5	65
39	Characterization of Chromosome 20q Deletions In Myeloproliferative Neoplasms Using Microarray Karyotyping and Next-Generation Sequencing. Blood, 2010, 116, 4099-4099.	1.4	65
40	Genetic and clinical heterogeneity of ferroportin disease. British Journal of Haematology, 2005, 131, 663-670.	2.5	64
41	Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica, 2011, 96, 607-611.	3.5	64
42	The JAK2ÂV617F mutation in patients with cerebral venous thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 998-1003.	3.8	61
43	Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. British Journal of Haematology, 2008, 140, 162-168.	2.5	60
44	Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica, 2011, 96, 167-170.	3.5	60
45	Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood, 2019, 134, 199-210.	1.4	54
46	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Blood, 2020, 135, 133-144.	1.4	52
47	Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Annals of Hematology, 2015, 94, 1927-1928.	1.8	51
48	Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood, 2016, 127, 362-365.	1.4	49
49	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a PCM1-JAK2 Fusion Gene. Journal of Clinical Oncology, 2013, 31, e269-e271.	1.6	47
50	Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. American Journal of Hematology, 2014, 89, 1107-1110.	4.1	47
51	Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases. Thrombosis Research, 2014, 134, 41-43.	1.7	47
52	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. American Journal of Hematology, 2016, 91, 918-922.	4.1	47
53	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	1.4	47
54	Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget, 2017, 8, 101735-101744.	1.8	45

#	Article	IF	Citations
55	Driver mutationsâ€™ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia, 2017, 31, 970-973.	7.2	41
56	JAK2 (V617F) mutation in healthy individuals. British Journal of Haematology, 2007, 136, 678-679.	2.5	40
57	Identification of genomic aberrations associated with disease transformation by means of highâ€resolution SNP array analysis in patients with myeloproliferative neoplasm. American Journal of Hematology, 2011, 86, 974-979.	4.1	37
58	Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. British Journal of Haematology, 2004, 126, 650-656.	2.5	36
59	LNK mutations in familial myeloproliferative neoplasms. Blood, 2016, 128, 144-145.	1.4	36
60	Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood, 2020, 135, 287-292.	1.4	34
61	A novel germline JAK2 mutation in familial myeloproliferative neoplasms. American Journal of Hematology, 2014, 89, 117-118.	4.1	31
62	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	3.5	31
63	Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica, 2015, 100, e443-e445.	3.5	30
64	CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer Journal, 2017, 7, 638.	6.2	27
65	Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. Journal of Internal Medicine, 2009, 265, 266-274.	6.0	26
66	Ruxolitinib treatment and risk of Bâ€cell lymphomas in myeloproliferative neoplasms. American Journal of Hematology, 2019, 94, E185-E188.	4.1	26
67	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.8	25
68	Cord blood in vitro expanded CD41+ cells: identification of novel components of megakaryocytopoiesis. Journal of Thrombosis and Haemostasis, 2006, 4, 848-860.	3.8	23
69	Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis. Blood, 2012, 120, 431-431.	1.4	19
70	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia, 2021, 35, 2371-2381.	7.2	17
71	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	2.8	16
72	Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 330-335.	4.1	15

#	Article	IF	Citations
73	Distinct Genetic Lesions Drive Leukemogenesis in Secondary Acute Myeloid Leukemia,. Blood, 2011, 118, 3559-3559.	1.4	15
74	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102.	0.8	13
75	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89.	6.2	13
76	Diagnosis and management of prefibrotic myelofibrosis. Expert Review of Hematology, 2018, 11, 537-545.	2.2	13
77	The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance. International Journal of Molecular Sciences, 2020, 21, 8885.	4.1	13
78	Type I but Not Type II Calreticulin Mutations Activate the IRE1Î±/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms. Blood Cancer Discovery, 2022, 3, 298-315.	5.0	12
79	Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplantation, 2010, 45, 798-800.	2.4	9
80	COLD-PCR and Innovative Microarray Substrates for Detecting and Genotyping MPL Exon 10 W515 Substitutions. Clinical Chemistry, 2012, 58, 1692-1702.	3.2	9
81	Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. PLoS ONE, 2013, 8, e77819.	2.5	9
82	PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia. Leukemia, 2005, 19, 888-889.	7.2	8
83	Blast phase of essential thrombocythemia: A single center study. American Journal of Hematology, 2009, 84, 641-644.	4.1	8
84	JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. American Journal of Hematology, 2012, 87, 746-747.	4.1	8
85	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	5.2	8
86	Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia.. Blood, 2009, 114, 435-435.	1.4	7
87	Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms. Oncotarget, 2017, 8, 33416-33421.	1.8	7
88	Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood, 2010, 115, 2719-2720.	1.4	6
89	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. International Journal of Cancer, 2016, 138, 1657-1669.	5.1	6
90	Allelic imbalance in CALR somatic mutagenesis. Leukemia, 2015, 29, 1431-1435.	7.2	5

#	Article	IF	Citations
91	Platelet count predicts driver mutationsâ€™ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis. Leukemia, 2021, 35, 1490-1493.	7.2	5
92	SF3B1 Mutation Is an Independent Predictor of Parenchymal Iron Overload in Myelodysplastic Syndromes. Blood, 2015, 126, 1678-1678.	1.4	4
93	Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage. Frontiers in Oncology, 2021, 11, 726637.	2.8	3
94	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	1.4	3
95	Chromosomal Aberration Network In Myeloproliferative Neoplasms. Blood, 2010, 116, 318-318.	1.4	3
96	Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms. Blood, 2022, 139, 2716-2720.	1.4	3
97	Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. American Journal of Hematology, 2012, 87, 129-130.	4.1	1
98	Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.. Blood, 2007, 110, 263-263.	1.4	1
99	Loss of Heterozygosity of Chromosome 1p34 and High Mutant Allele Burden in Patients with Post-Essential Thrombocythemia Myelofibrosis Carrying Somatic Mutations of MPL. Blood, 2008, 112, 176-176.	1.4	1
100	Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin. Blood, 2014, 124, 3215-3215.	1.4	1
101	Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients. Blood, 2015, 126, 351-351.	1.4	1
102	Fusion Gene Detection Using Whole Transcriptome Analysis in Patients with Chronic Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia. Blood, 2015, 126, 4093-4093.	1.4	1
103	JAK2 (V617F)-Positive Essential Thrombocythemia and Polycythemia Vera Are Different Expressions Of a Genotypic/Phenotypic Continuum. Blood, 2013, 122, 1592-1592.	1.4	1
104	Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms. Blood, 2015, 126, 606-606.	1.4	1
105	Common Variation at 6q25.3 (TULP4) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms. Blood, 2015, 126, 4088-4088.	1.4	1
106	Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group. Blood, 2016, 128, 943-943.	1.4	1
107	Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN. Leukemia and Lymphoma, 2021, 62, 1782-1785.	1.3	0
108	Sequential Evaluation of the Proportion of Granulocyte JAK2 (V617F) Mutant Alleles in Chronic Myeloproliferative Disorders.. Blood, 2006, 108, 2682-2682.	1.4	0

#	Article	IF	Citations
109	Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.. Blood, 2012, 120, 2854-2854.	1.4	0
110	Clonal Analysis of SF3B1, JAK2 and MPL in Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis. Blood, 2012, 120, 172-172.	1.4	0
111	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated with t(8;9)(p22;p24) and PCM1-JAK2 Fusion Gene.. Blood, 2012, 120, 2833-2833.	1.4	0
112	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. Blood, 2013, 122, 1600-1600.	1.4	0
113	Whole Exome Sequencing Reveals Clonal Evolution of Myeloproliferative Neoplasms to Acute Myeloid Leukemia. Blood, 2015, 126, 1626-1626.	1.4	0
114	The Impact of Driver Mutations of JAK2, Calr, or MPL in Patients with Myelofibrosis Undergoing Hemopoietic Stem Cell Transplantation. Blood, 2015, 126, 5405-5405.	1.4	0
115	Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms. EJHaem, 0, , .	1.0	0